Clinical Trials


Recent clinical trials in nuclear medicine. Sorted by date of last update.

Title Phase Last Update

Comparing Retreatment of 177Lu-DOTATATE PRRT versus Everolimus in Patients with Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Phase 2

Last update: Feb 14, 2025

Phase 2 Feb 14, 2025

Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer (68Ga-PSMA)

Phase N/A

Last update: Feb 14, 2025

Phase N/A Feb 14, 2025

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination with Capecitabine in Patients with GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination with a CDK4/6 Inhibitor. (NeoB-Cap1)

Phase 1

Last update: Feb 14, 2025

Phase 1 Feb 14, 2025

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults with Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study (RADIODOSE)

Phase 1

Last update: Feb 14, 2025

Phase 1 Feb 14, 2025

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan versus Observation in PSMA Positive OMPC. (PSMA-DC)

Phase 3

Last update: Feb 14, 2025

Phase 3 Feb 14, 2025

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

Phase 1

Last update: Feb 14, 2025

Phase 1 Feb 14, 2025

[177Lu]Lu-NeoB in Combination with Ribociclib and Fulvestrant in Participants with ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1

Last update: Feb 14, 2025

Phase 1 Feb 14, 2025

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Phase 1

Last update: Feb 14, 2025

Phase 1 Feb 14, 2025

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (Rad2Nivo)

Phase 1

Last update: Feb 13, 2025

Phase 1 Feb 13, 2025

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Phase 2

Last update: Feb 13, 2025

Phase 2 Feb 13, 2025